Ji Yeon Kim1, Keon Jae Park2, Joo-Yeon Hwang3, Gyu Hee Kim1, DaeYeon Lee4, Yoo Jeong Lee1, Eun Hyun Song1, Min-Gyu Yoo1, Bong-Jo Kim5, Young Ho Suh6, Gu Seob Roh7, Bin Gao8, Won Kim9, Won-Ho Kim10. 1. Division of Metabolic Disease, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea. 2. Division of Metabolic Disease, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea; Department of Anatomy and Cardiology, Chungbuk University, Chungbuk, Republic of Korea. 3. Division of Cardiovascular and Rare Disease, Center for Biomedical Science, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea; Division of Structural and Functional Genomics, Center for Genomic Science, National Institute of Health, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea. 4. Division of Metabolic Disease, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea; Department of Biotechnology, Korea University, Seoul, Republic of Korea. 5. Division of Structural and Functional Genomics, Center for Genomic Science, National Institute of Health, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea. 6. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. 7. Department of Anatomy and Neurobiology, Gyeongsang National University, Jinju, Gyeongnam, Republic of Korea. 8. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA. 9. Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. Electronic address: drwon1@snu.ac.kr. 10. Division of Metabolic Disease, #187 Osong Saengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 363-700, Republic of Korea. Electronic address: jhkwh@nih.go.kr.
Abstract
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) contributes to impaired glucose tolerance, leading to type 2 diabetes (T2D); however, the precise mechanisms and target molecules that are involved remain unclear. Activating transcription factor 3 (ATF3) is associated with β-cell dysfunction that is induced by severe stress signals in T2D. We aimed to explore the exact functional role of ATF3 as a mechanistic link between hepatic steatosis and T2D development. METHODS: Zucker diabetic fatty (ZDF) rats were utilized for animal experiments. An in vivo-jetPEI siRNA delivery system against ATF3 was used for loss-of-function experiments. We analyzed the baseline cross-sectional data derived from the biopsy-proven NAFLD registry (n=322). Human sera and liver tissues were obtained from 43 patients with biopsy-proven NAFLD and from seven healthy participants. RESULTS: ATF3 was highly expressed in the livers of ZDF rats and in human participants with NAFLD and/or T2D. Insulin resistance and hepatic steatosis were associated with increased ATF3 expression and decreased fatty acid oxidation via mitochondrial dysfunction and were attenuated by in vivo ATF3 silencing. Knockdown of ATF3 also ameliorated glucose intolerance, impaired insulin action, and inflammatory responses in ZDF rats. In patients with NAFLD and/or T2D, a significant positive correlation was observed between hepatic ATF3 expression and surrogate markers of T2D, mitochondrial dysfunction, and macrophage infiltration. CONCLUSIONS: Increased hepatic ATF3 expression is closely associated with hepatic steatosis and incident T2D; therefore, ATF3 may serve as a potential therapeutic target for NAFLD and hepatic steatosis-induced T2D. LAY SUMMARY: Hepatic activating transcription factor 3 (ATF3) may play an important role in oxidative stress-mediated hepatic steatosis and the development of type 2 diabetes (T2D) in a Zucker diabetic fatty (ZDF) rat model and in human patients with non-alcoholic fatty liver disease (NAFLD). Therefore, ATF3 may be a useful biomarker for predicting the progression of NAFLD and the development of T2D. Furthermore, given the significant association between hepatic ATF3 expression and both hepatic steatosis and impaired glucose homeostasis, in vivo ATF3 silencing may be a potential central strategy for preventing and managing NAFLD and T2D.
BACKGROUND & AIMS:Non-alcoholic fatty liver disease (NAFLD) contributes to impaired glucose tolerance, leading to type 2 diabetes (T2D); however, the precise mechanisms and target molecules that are involved remain unclear. Activating transcription factor 3 (ATF3) is associated with β-cell dysfunction that is induced by severe stress signals in T2D. We aimed to explore the exact functional role of ATF3 as a mechanistic link between hepatic steatosis and T2D development. METHODS:Zucker diabetic fatty (ZDF) rats were utilized for animal experiments. An in vivo-jetPEI siRNA delivery system against ATF3 was used for loss-of-function experiments. We analyzed the baseline cross-sectional data derived from the biopsy-proven NAFLD registry (n=322). Human sera and liver tissues were obtained from 43 patients with biopsy-proven NAFLD and from seven healthy participants. RESULTS:ATF3 was highly expressed in the livers of ZDFrats and in humanparticipants with NAFLD and/or T2D. Insulin resistance and hepatic steatosis were associated with increased ATF3 expression and decreased fatty acid oxidation via mitochondrial dysfunction and were attenuated by in vivo ATF3 silencing. Knockdown of ATF3 also ameliorated glucose intolerance, impaired insulin action, and inflammatory responses in ZDFrats. In patients with NAFLD and/or T2D, a significant positive correlation was observed between hepatic ATF3 expression and surrogate markers of T2D, mitochondrial dysfunction, and macrophage infiltration. CONCLUSIONS: Increased hepatic ATF3 expression is closely associated with hepatic steatosis and incident T2D; therefore, ATF3 may serve as a potential therapeutic target for NAFLD and hepatic steatosis-induced T2D. LAY SUMMARY: Hepatic activating transcription factor 3 (ATF3) may play an important role in oxidative stress-mediated hepatic steatosis and the development of type 2 diabetes (T2D) in a Zucker diabetic fatty (ZDF) rat model and in humanpatients with non-alcoholic fatty liver disease (NAFLD). Therefore, ATF3 may be a useful biomarker for predicting the progression of NAFLD and the development of T2D. Furthermore, given the significant association between hepatic ATF3 expression and both hepatic steatosis and impaired glucose homeostasis, in vivo ATF3 silencing may be a potential central strategy for preventing and managing NAFLD and T2D.
Keywords:
Activation transcription factor 3; Human patients; In vivo silencing; Non-alcoholic fatty liver disease; Oxidative stress; Zucker diabetic fatty rat
Authors: Seung Mi Lee; Soo Heon Kwak; Ja Nam Koo; Ig Hwan Oh; Jeong Eun Kwon; Byoung Jae Kim; Sun Min Kim; Sang Youn Kim; Gyoung Min Kim; Sae Kyung Joo; Bo Kyung Koo; Sue Shin; Chanthalakeo Vixay; Errol R Norwitz; Chan-Wook Park; Jong Kwan Jun; Won Kim; Joong Shin Park Journal: Diabetologia Date: 2018-11-23 Impact factor: 10.122
Authors: Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg Journal: Proc Natl Acad Sci U S A Date: 2021-04-06 Impact factor: 11.205
Authors: Sara A Beddow; Arijeet K Gattu; Daniel F Vatner; Lauren Paolella; Abdulelah Alqarzaee; Nedda Tashkandi; Violeta B Popov; Christopher D Church; Matthew S Rodeheffer; Gary W Cline; John G Geisler; Sanjay Bhanot; Varman T Samuel Journal: Endocrinology Date: 2019-01-01 Impact factor: 4.736
Authors: Mohammed A Assiri; Hadi R Ali; John O Marentette; Youngho Yun; Juan Liu; Matthew D Hirschey; Laura M Saba; Peter S Harris; Kristofer S Fritz Journal: Hum Genomics Date: 2019-12-10 Impact factor: 4.639